Mutagenesis of the rapamycin producer Streptomyces hygroscopicus FC904.
Rapamycin (RPM) is produced by Streptomyces hygroscopicus FC904 isolated from soil in Fuzhou, China. It is a triene macrolide antibiotic with potential application as an immunosuppressant and drug for human gene therapy. In an attempt to improve rapamycin production, mutation and screening of the parent culture have been carried out. Thousands of survivors were obtained after mutagenesis by NTG (3 mg/ml) and UV (30 W, 15 cm, 30 seconds) of spore suspensions. None showed improved production of RPM. We determined the susceptibility to antibiotics of S. hygroscopicus FC904 by two fold dilutions of antibiotics in oatmeal agar plates. It was found that the strain was resistant to penicillin, erythromycin, RPM, tetracycline and chloramphenicol, but susceptible to mitomycin C (MIC, 10 microg/ml) and aminoglycosides such as gentamicin (MIC, 0.1 microg/ml), kanamycin (MIC, 0.1 microg/ml) and streptomycin (MIC, 0.3 microg/ml). Protoplasts of strain FC904 were prepared after finding the best conditions for their formation. They were treated with gentamicin, erythromycin, mitomycin C and NTG. Surprisingly, gentamicin was especially effective for obtaining higher RPM-producing mutants. Mutant C14 was selected by exposing the protoplasts of the parent strain FC904 to 1 microg/ml of gentamicin at 28 degrees C for 2 hours. A higher RPM-producing mutant (C14-1) was obtained from the protoplasts of mutant C14 treated with gentamicin, and its titer was 60% higher than that of the parent strain FC904 by HPLC analysis. Another improved mutant (C14-2) was obtained from the spores of mutant C 14 treated with 1 microg/ml of gentamicin plus 2 mg/ml of NTG at 28 degrees C for 2 hours. Mutant C14-2 had a titer 124% higher than FC904. The possible mechanism for the effect of gentamicin by using protoplasts or spore suspensions will be discussed, i.e. the possibility of gentamicin being a mutagen or a selective agent.
Cheng
Y R
YR
Institute of Microbiology, State Pharmaceutical Administration of China and Fujian Province, Fuzhou. fim@pub3.fz.fj.cn
Huang
J
J
Qiang
H
H
Lin
W L
WL
Demain
A L
AL
D000900:Anti-Bacterial Agents / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid; D008769:Methylnitronitrosoguanidine / Q000737:chemistry; D008826:Microbial Sensitivity Tests; D016296:Mutagenesis; D011523:Protoplasts / Q000378:metabolism; D020123:Sirolimus / Q000378:metabolism*; D013302:Streptomyces / Q000187:drug effects / Q000235:genetics* / Q000378:metabolism / Q000528:radiation effects; D014466:Ultraviolet Rays
D000900:Anti-Bacterial Agents; D008769:Methylnitronitrosoguanidine; D020123:Sirolimus